Translational Cancer Research 2024 CiteScore Released: 2.5

We are pleased to announce that the Translational Cancer Research (TCR) has achieved its 2024 CiteScore: 2.5. TCR ranks as follows across various categories: 261 out of 415 in Oncology, 180 out of 233 in Cancer Research, and 191 out of 346 in Radiology, Nuclear Medicine and Imaging. This milestone underscores our ongoing commitment to publishing impactful research in the field.

Read More>>

Reviewer of the Month (2025)

In 2025, TCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

Interviews with Outstanding Authors (2025)

In 2025, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Read More>>

TCR 2024 Annual Report

Greetings from the Editorial Office of TCR!

We are pleased to share the 2024 Annual Report of Translational Cancer Research. 2024 has seen much progress for TCR. We hope 2025 will bring greater things to TCR. We would like to thank you for your support and assistance in improving the journal over the past year, and we certainly look forward to your innovations and contributions in 2025.

We would especially like to express our sincere gratitude to the editorial board members, guest editors, reviewers, authors, and readers for all your support and contributions to TCR. We wish you a happy, healthy and prosperous 2025!

Read More>>

Interviews with Editorial Board Members

TCR features a distinguished editorial board, the members of which continue to instill the power of their expertise for the journal’s development. By launching this column, we are glad to introduce to you some of them in the form of interviews, in which they will share their unique career experiences and perspectives. We believe their insights will shed light on the knowledge of related fields.

Read More>>

Interviews with Guest Editors

Over the years, a number of TCR guest editors have made valuable contributions to the journal. This column features interviews with our guest editors, who graciously share their experience in scientific careers and provide insightful perspectives on the special series.

Read More>>

Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases

Identification of differentially expressed genes. (A) Heatmap revealed differentially expressed genes; (B) univariate Cox regression analysis; (C) a protein-protein interaction network showing the relationship between ferroptosis-related genes and cuproptosis-related genes.

Read More>>

Bartholin’s gland carcinoma—the diagnostic and management challenges of a rare malignancy—a case report and review of current literature

FDG-avid right inguinal lymph node on axial CT-PET. The green arrow: FDG-avid right inguinal lymph node on axial CT-PET. FDG, fluorodeoxyglucose; CT-PET, computed tomography-positron-emission tomography.

Read More>>

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme

Differences in risk scores for clinical characteristics. (A-D) The correlations between the risk score and sex, age, MGMT status, and IDH1 status were not significant (P>0.05). (E) Among the subtypes, the proneural subtypes had a significantly lower risk score than did the mesenchymal subtypes (P<0.05). **, P<0.01. IDH1, isocitrate dehydrogenase 1; MGMT, O6-methylguanine-DNA methyltransferase; ns, no significance.

Read More>>

Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma

Single-cell sequencing analysis of 20,074 cells from 7 ccRCC samples. (A) Pearson’s correlation between nFeature and nCount. (B) PCA plot colored by different samples. (C) Cells were classified into 25 clusters via UMAP algorithm. (D) Eight cell types were identified and annotated by marker genes. (E) Heatmap visualized top 5 marker genes among 8 cell clusters. (F) Visualization of gene expression in cell clusters. PC, principal component; UMAP, uniform manifold approximation and projection; NK, nature killer; ccRCC, clear cell renal cell carcinoma; PCA, principal component analysis.

Read More>>

Development and validation of nomograms to predict early death in non-small cell lung cancer patients with brain metastasis: a retrospective study in the SEER database

ROC curves for the nomograms of the all-cause early death and the cancer-specific early death in the training cohort (A,B) as well as in the validation cohort (C,D). ROC, receiver operating characteristic; AUC, area under the curve.

Read More>>